Hong Kong medical journal = Xianggang yi xue za zhi·2021
This study developed a primate glaucoma model to test intraocular pressure-lowering drugs. Several medications, including timolol and prostaglandin F2 alpha, effectively reduced eye pressure.
Area of Science:
Ophthalmology
Pharmacology
Veterinary Medicine
Background:
Glaucoma is a leading cause of irreversible blindness.
Accurate animal models are crucial for developing effective glaucoma treatments.
Trabecular meshwork photocoagulation in primates offers a robust model for studying intraocular pressure regulation.
Purpose of the Study:
To establish and validate a cynomolgus monkey model of induced glaucoma.
To evaluate the efficacy of various pharmacological agents in lowering intraocular pressure (IOP) within this model.
To assess the impact of these agents on aqueous humor outflow facility.
Main Methods:
Glaucoma was induced in cynomolgus monkeys using argon laser photocoagulation of the trabecular meshwork.
Intraocular pressure was measured hourly using a pneumatonometer before and after drug administration.
The effects of timolol, epinephrine, pilocarpine, vanadate, prostaglandin F2 alpha (PGF2 alpha), forskolin, and corynanthine were tested.
Main Results:
Significant IOP reductions (p < 0.05) were observed with timolol, epinephrine, pilocarpine, vanadate, PGF2 alpha, and forskolin.
Corynanthine did not produce a significant IOP-lowering effect.
Pilocarpine administration increased outflow facility, indicating a mechanism of action.
Conclusions:
The induced primate glaucoma model demonstrates characteristic IOP fluctuations and is responsive to various IOP-lowering drugs.
This model is suitable for investigating novel therapeutic agents targeting different mechanisms of IOP reduction.
Pharmacological agents like timolol, epinephrine, and prostaglandin F2 alpha show promise for glaucoma management.